Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in targeted therapy: safety of biological agents.

Literature DB >> 14532146

Advances in targeted therapy: safety of biological agents.

E C Keystone¹.

Abstract

Mesh：

Substances：

Year: 2003 PMID： 14532146 PMCID： PMC1766742 DOI： 10.1136/ard.62.suppl_2.ii34

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

12 in total

1. Prescription-event monitoring and reporting of adverse drug reactions.

Authors: E Heeley; J Riley; D Layton; L V Wilton; S A Shakir
Journal: Lancet Date: 2001-12-01 Impact factor: 79.321

2. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors: E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal: BMJ Date: 1998-07-18

3. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.

Authors: Karin Ekström; Henrik Hjalgrim; Lena Brandt; Eva Baecklund; Lars Klareskog; Anders Ekbom; Johan Askling
Journal: Arthritis Rheum Date: 2003-04

4. Rhode Island physicians' recognition and reporting of adverse drug reactions.

Authors: H D Scott; S E Rosenbaum; W J Waters; A M Colt; L G Andrews; J P Juergens; G A Faich
Journal: R I Med J Date: 1987-07

5. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

Authors: T ten Hove; C van Montfrans; M P Peppelenbosch; S J H van Deventer
Journal: Gut Date: 2002-02 Impact factor: 23.059

6. Rheumatoid arthritis and cancer risk.

Authors: L Mellemkjaer; M S Linet; G Gridley; M Frisch; H Møller; J H Olsen
Journal: Eur J Cancer Date: 1996-09 Impact factor: 9.162

7. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.

Authors: A Lügering; M Schmidt; N Lügering; H G Pauels; W Domschke; T Kucharzik
Journal: Gastroenterology Date: 2001-11 Impact factor: 22.682

8. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition.

Authors: P Emery; G Panayi; D Symmons; G Brown
Journal: Ann Rheum Dis Date: 1984-06 Impact factor: 19.103

Review 9. Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

Authors: Hyon J Kwon; Timothy R Coté; Michael S Cuffe; Judith M Kramer; M Miles Braun
Journal: Ann Intern Med Date: 2003-05-20 Impact factor: 25.391

10. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.

Authors: M D Rawlins
Journal: J R Coll Physicians Lond Date: 1995 Jan-Feb

8 in total

1. [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].

Authors: U Müller-Ladner
Journal: Internist (Berl) Date: 2004-12 Impact factor: 0.743

2. Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events.

Authors: L Konttinen; V Honkanen; T Uotila; J Pöllänen; M Waahtera; M Romu; K Puolakka; M Vasala; A Karjalainen; R Luukkainen; D C Nordström
Journal: Rheumatol Int Date: 2006-01-10 Impact factor: 2.631

3. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience.

Authors: Liisa Konttinen; Riitta Tuompo; Tea Uusitalo; Riitta Luosujärvi; Kari Laiho; Jukka Lähteenmäki; Maija Puurtinen-Vilkki; Ritva Lanteri; Saara Kortelainen; Helena Karilainen; Tuire Varjolahti-Lehtinen; Dan Nordström
Journal: Clin Rheumatol Date: 2007-03-01 Impact factor: 2.980

Review 4. TNF-alpha and its inhibitors in cancer.

Authors: Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal: Med Oncol Date: 2009-03-11 Impact factor: 3.064

Review 5. Infliximab: 12 years of experience.

Authors: Josef S Smolen; Paul Emery
Journal: Arthritis Res Ther Date: 2011-05-25 Impact factor: 5.156